NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
NuVasive Stock Up 1.0 %
NUVA Stock traded up $0.53 during trading hours on Monday, hitting $54.02. The company's stock had a trading volume of 586,153 shares, compared to its average volume of 544,291. The company has a quick ratio of 0.70, a current ratio of 1.17 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $2.81 billion, a PE ratio of -67.53, a price-to-earnings-growth ratio of 2.13 and a beta of 1.14. NuVasive has a 12 month low of $45.45 and a 12 month high of $64.43. The stock has a 50 day moving average price of $50.80 and a two-hundred day moving average price of $52.77.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of NuVasive from $50.00 to $55.00 in a report on Friday, August 5th. Morgan Stanley dropped their price objective on shares of NuVasive from $62.00 to $54.00 and set an "equal weight" rating on the stock in a research note on Friday, July 15th. Piper Sandler dropped their price objective on shares of NuVasive from $80.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, August 4th. Finally, Truist Financial dropped their price objective on shares of NuVasive to $63.00 in a research note on Friday, July 22nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, NuVasive presently has a consensus rating of "Hold" and a consensus price target of $61.75.